COSELA shields helping to protect a neutrophil and red blood cell while a chemotherapy arrow targets cancer cells

NEW to decrease the incidence of chemotherapy-induced myelosuppression in patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen

For extensive-stage small cell lung cancer (ES-SCLC)

SPARE THE MARROW. SPEAR THE TUMOR.

COSELA HELPS PROTECT AGAINST myelosuppression, while chemotherapy targets cancer cells

COSELA™ (trilaciclib) helps protect hematopoietic stem and progenitor cells (HSPCs), the source of blood cell lineages

FDA Breakthrough
Therapy Designation

Proactively help protect against multiple myelosuppressive consequences with the first and only myeloprotection therapy

The First and Only Therapy for Proactive Multilineage Myeloprotection

COSELA is the first and only FDA-approved therapy to provide myeloprotective efficacy. COSELA has been evaluated in studies based on endpoints across multiple lineages, including:

  • Severe neutropenia (primary endpoints)
  • Grade 3/4 anemia and red blood cell (RBC) transfusions (secondary endpoints)
  • Rate of chemotherapy dose reductions (secondary endpoint)
See Study Design > See Myeloprotective Efficacy >

INTEGRATED SAFETY ACROSS STUDIES

The most common adverse reactions (≥10%) were fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia.

See Safety Data >
Neutrophil cell
Neutrophil cell Neutrophil cell Neutrophil cell

HELP PROTECT AGAINST SEVERE NEUTROPENIA

View Data >
Red blood cell
Red blood cell Red blood cell

STUDIED ACROSS MULTIPLE RBC-RELATED ENDPOINTS

View Data >

INDICATION: COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

THE FIRST & ONLY MYELOPROTECTION THERAPY

COSELA helps protect hematopoietic stem and progenitor cells (HSPCs), the source of multiple blood cell lineages. See the mechanism of action (MOA) of COSELA.

See the MOA >